Immunohistochemical study of CD44 in сolorectal adenocarcinoma

Authors

  • M. A. Shyshkin Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine, Ukraine
  • T. A. Khrystenko Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine, Ukraine https://orcid.org/0000-0003-3364-3339

DOI:

https://doi.org/10.26641/1997-9665.2020.2.44-50

Keywords:

colorectal cancer, CD44 Antigen

Abstract

Background. Over the last decade, a significant amount of data supporting the cancer stem cell hypothesis has been accumulated. Despite the large number of works devoted to the study of the stem cell marker CD44 in colorectal adenocarcinoma, the question of the prognostic value of this marker is still controversial. Objective. To study CD44 immunohistochemical expression in colorectal adenocarcinoma on the I, II, III, IV stages (pTNM). Methods. Pathohistological and immunohistochemical studies of surgical material from 30 patients that underwent surgical treatment of colorectal adenocarcinoma (I–IV stages) were carried out. Polyclonal antibodies CD44 (CD44 Std. / HCAM Ab-4, Thermo Scientifiс, USA) were used for immunohistochemical study. Results. 16,7% of all the studied cases were stage I colorectal adenocarcinomas, 26,7% – stage II colorectal adenocarcinomas, 33,3% – stage III colorectal adenocarcinomas, and 23,3% – stage IV colorectal adenocarcinomas. It was established that colorectal adenocarcinoma is characterized by the medium membrano-cytoplasmic expression of CD44 with the median 90,49 (62,19; 110,15) CUOD that statistically significantly higher than CD44 expression level in non-changed mucosa of the distal colon. There is a tendency to increasing of expression level of the marker in sequence of the stages of colorectal adenocarcinoma development, wherein median of CD44 expression in stage II carcinomas is significantly higher than the same characteristic in stage I carcinomas (70,32 (55,13; 90,56) CUOD vs. 51,12 (31,14; 60,32) CUOD, р˂0,05), and median of CD44 expression in stage III carcinomas is significantly higher than the same characteristic in stage II carcinomas (104,76 (90,03; 112,26) CUOD vs. 70,32 (55,13; 90,56) CUOD, р˂0,05). Furthermore, correlations between CD44 expression level and depth of tumor’s invasion (r=0,48, p˂0,05), presence of regional metastases (r=0,53, p˂0,05), presence of distant metastases (r=0,38, p˂0,05), histological grade of the tumor (r=0,27, p˂0,05) were revealed. Conclusion. CD44 immunohistochemical expression increases significantly during the progression of colorectal adenocarcinoma from stage I to stage III (pTNM), as well it correlates with depth of the tumor’s invasion, presence of regional and distant metastases, and with histological grade of the tumor.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L., Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
  2. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103.
  3. Moharil RB, Dive A, Khandekar S, Bodhade A. Cancer stem cells: An insight. J Oral Maxillofac Pathol. 2017;21(3):463.
  4. Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381-95.
  5. Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781.
  6. Kuşoğlu A., Biray Avcı Ç. Cancer stem cells: A brief review of the current status. Gene. 2019;681:80-5.
  7. Capp J. Cancer Stem Cells: From Historical Roots to a New Perspective. Journal of Oncology. 2019;2019:1-10.
  8. Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z, Wang K, Zong S. The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Frontiers in Oncology. 2019;9:309.
  9. Morath I, Hartmann T, Orian-Rousseau V. CD44: More than a mere stem cell marker. The International Journal of Biochemistry & Cell Biology. 2016;81:166-73.
  10. Wang L, Zuo X, Xie K, Wei D. The Role of CD44 and Cancer Stem Cells. Methods Mol Biol. 2018;1692:31-42.
  11. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.
  12. Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol. 2017;5:18.
  13. Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, Lin J, Tan S, Tian Y, Liao Q, Cao D. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2017;9(70):33403-15.
  14. Xia P, Xu X. Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses. Oncotarget. 2016;7(29):45538-46.
  15. Inoue K, Fry E. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genetics & Epigenetics. 2015;7:19-32.
  16. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. New York: Wiley-Blackwell, 2009, 50 pp.
  17. Dayer C, Stamenkovic I. Recruitment of Matrix Metalloproteinase-9 (MMP-9) to the Fibroblast Cell Surface by Lysyl Hydroxylase 3 (LH3) Triggers Transforming Growth Factor-β (TGF-β) Activation and Fibroblast Differentiation. The Journal of Biological Chemistry. 2015;290:13763-78.
  18. Preca BT, Baidak K, Mock K, Sundararajan V, Pfannstiel J, Maurer J, Wellner U, Hopt U, T, Brummer T, Brabletz S, Brabletz T, Stemmler MP. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer. 2015;137(11):2566-77. https://doi.org/ 10.1002/ijc.29642

Downloads

How to Cite

Shyshkin, M. A., & Khrystenko, T. A. (2020). Immunohistochemical study of CD44 in сolorectal adenocarcinoma. Морфологія / Morphologia / Morfologìâ, 14(2), 44–50. https://doi.org/10.26641/1997-9665.2020.2.44-50

Issue

Vol. 14 No. 2 (2020)

Section

Статті

License

Copyright (c) 2020 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.